Toronto-based Xagenic Inc has closed a syndicated Series A financing for $10 million to develop new technology for rapid diagnostic testing. Funding for the privately held molecular diagnostics firm was provided by CTI Life Sciences, Ontario Emerging Technologies Fund and QIAGEN NV. The financing follows a $2.2-million seed round in 2010 led by MaRS Innovation. The company's testing platform will be used in hospitals, clinics and physicians' offices....
Other stories mentioning these organizations, people and topics
| Organizations: | CTI Life Sciences, Ontario Emerging Technologies Fund, QIAGEN NV, and Xagenic Inc |
Other News
Events For Leaders in
Science, Tech, Innovation, and Policy
Discuss and learn from those in the know at our virtual and in-person events.
See Upcoming Events
You have 1 free article remaining.
Don't miss out - start your free trial today.
Start your FREE trial Already a member? Log in
By using this website, you agree to our use of cookies. We use cookies to provide you with a great experience and to help our website run effectively in accordance with our Privacy Policy and Terms of Service.